Gradalis Inc. isn't your typical biotech startup. With nearly $90M in funding and a pipeline of personalized cancer therapeutics, you'd expect a digital footprint that commands respect. Instead, gradalisinc.com is a ghost town—a stark reminder that in the high-stakes world of drug development, a website is often an afterthought.

"This isn't a marketing failure; it's a strategic signal. In biotech, you don't need a flashy website—you need a drug that works."

The tech stack tells the same story. Using jQuery, Tailwind CSS, and Bootstrap—technologies that are functional but dated—signals a 'set it and forget it' approach. The site is hosted on AWS CloudFront with Cloudflare protection, prioritizing uptime over innovation. This isn't a digital-first company; it's a science-first company with a website that simply exists.

• Traffic is essentially zero: 15 visits per month suggests the site is used primarily by internal stakeholders and regulatory bodies.
• The 'undefined' country data is a red flag for analytics setup, indicating a lack of sophisticated tracking.
• Vigil is the only keyword that matters, but the site doesn't rank for it—clinical data is hosted on medical journals, not corporate websites.